Gilead Sciences, Inc.GILDNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank69
5Y CAGR-14.8%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-14.8%/yr
Long-term compound
Percentile
P69
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 16.27% |
| Q3 2025 | -9.73% |
| Q2 2025 | 8.12% |
| Q1 2025 | -15.97% |
| Q4 2024 | 17.63% |
| Q3 2024 | 3.26% |
| Q2 2024 | -11.12% |
| Q1 2024 | 7.95% |
| Q4 2023 | -3.36% |
| Q3 2023 | 3.55% |
| Q2 2023 | -2.76% |
| Q1 2023 | 225.61% |
| Q4 2022 | -200.26% |
| Q3 2022 | 4.26% |
| Q2 2022 | -71.58% |
| Q1 2022 | 91.32% |
| Q4 2021 | 84.11% |
| Q3 2021 | 0.82% |
| Q2 2021 | 3.51% |
| Q1 2021 | -33.14% |
| Q4 2020 | 36.27% |
| Q3 2020 | -10.85% |
| Q2 2020 | 29.38% |
| Q1 2020 | -47.13% |
| Q4 2019 | 84.37% |
| Q3 2019 | 3.52% |
| Q2 2019 | -5.87% |
| Q1 2019 | -45.79% |
| Q4 2018 | 107.67% |
| Q3 2018 | -21.22% |
| Q2 2018 | 27.21% |
| Q1 2018 | -18.52% |
| Q4 2017 | 45.75% |
| Q3 2017 | -8.68% |
| Q2 2017 | -7.20% |
| Q1 2017 | -22.93% |
| Q4 2016 | 5.87% |
| Q3 2016 | -23.11% |
| Q2 2016 | 17.31% |
| Q1 2016 | 67.11% |